BMP Sunstone Corporation said its Clinical Trial Application for Enablex® (Darifenacin) was accepted by the SFDA, allowing the company to begin clinical trials of the treatment for overactive bladder (OAB). BMP will start human trials in the first half of 2009 and expects that approval will follow sometime in 2011. Novartis, which owns Enablex, signed an agreement with BMP Sunstone in November 2007, authorizing the company to seek marketing approval for the drug. If the drug is approved for use in China, BMP Sunstone will have ten years of marketing exclusivity for Enablex. More details...

Stock Symbols: (NSDQ: BJGP) (NYSE: NVS) (NYSE: PFE)